Deutsche Bank analysts suggest the company's statement on ad...

Deutsche Bank analysts suggest the company's statement on additional divestiture actions likely refers to a potential sale of its Pharma Solutions business. They see this as the most logical way for the company to meet its '24 net debt-to-EBITDA target of <3x. IFF's high leverage is seen as a key reason for its 3x EBITDA multiple valuation discount to peers.